Rheumatoid arthritis databases in Finland

Clinical and Experimental Rheumatology

Volumn 23, Issue 5 SUPPL. 39, 2005, Pages

  Sokka, Tuulikki ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Database; Longitudinal observational studies; Rheumatoid arthritis; Rheumatology

Indexed keywords

HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PREDNISOLONE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DATA BASE; FINLAND; HEALTH STATUS; HUMAN; INCIDENCE; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; WORK DISABILITY; ADVERSE DRUG REACTION; ARTICLE; CANCER RISK; CLINICAL OUTCOME; COHORT ANALYSIS; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SURVEY; LONGITUDINAL STUDY; MULTICENTER STUDY; PREDICTION; PREMATURE MORTALITY; PROSPECTIVE STUDY; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYNOVECTOMY; TREATMENT RESPONSE; CONTROLLED STUDY; FACTUAL DATABASE; HOSPITALIZATION; METHODOLOGY; RHEUMATOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; FINLAND; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644795377     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
2. WOLFE F, LASSERE M, VAN DER HEIJDE D et al.: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. Omeract IV: Outcome measures in rheumatology. Cancun, Mexico, April 16-20, 1998. J Rheumatol 1999; 26: 484-9.
3. KVIEN TK, UHLIG T: The Oslo experience with arthritis registries. Clin Exp Rheumatol 2003; 21: 8118-8122.
4. Dr. Frederick Wolfe, personal communication, 2004.
5. SOKKA T: Early rheumatoid arthritis in Finland. Clin Exp Rheumatol 2003; 21: S133-S137.
6. SOKKA T, HANNONEN P, MOTTONEN T: Conventional DMARDs in early arthritis. Rheum Dis Clin North Am (in press).
7. JANTTI JK, KAARELA K, BELT EA, KAUTIAINEN HJ: Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol 2002; 29: 688-92.
8. PALM TM, KAARELA K, HAKALA MS, KAUTIAINEN HJ, KROGER HPJ, BELT EA: Need and sequence of large joint replacements in rheumatoid arthritis. A 25-year follow-up study. Clin Exp Rheumatol 2002; 20: 392-4.
9. PELTOMAA R, LEIRISALO-REPO M, HELVE T, PAIMELA L: Effect of age on 3 year outcome in early rheumatoid arthritis. J Rheumatol 2000; 27: 638-43.
10. MÖTTÖNEN TT: Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988; 47: 648-53.
11. HANNONEN P, MÖTTÖNEN T, HAKOLA M, OKA M: Sulfasalazine in early rheumatoid arthritis. Arthritis Rheum 1993; 36: 1501-9.
12. SOKKA T, MÖTTÖNEN T, HANNONEN P: Disease-modifying anti-rheumatic drug use according to the 'sawtooth' treatment strategy improves the functional outcome in rheumatoid arthritis: Results of a long-term follow-up study with review of the literature. Rheumatology 2000; 39: 34-42.
13. SOKKA T, KAUTIAINEN H, HÄKKINEN K, HANNONEN P: Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004; 31: 1073-82.
14. MÖTTÖNEN T, HANNONEN P, LEIRISALO-REPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-73.
15. KORPELA M, LAASONEN L, HANNONEN P et al.: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50: 2072-81.
16. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T et al.: Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized followup trial. Arthritis Rheum 2004; 50: 55-62.
17. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T et al.: Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005; 64: 130-3.
18. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T, HANNONEN P, KORPELA M: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36-41.
19. SOKKA T, KRISHNAN E, HÄKKINEN A, HANNONEN P: Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48: 59-63.
20. KRISHNAN E, SOKKA T, HÄKKINEN A, HUBERT H, HANNONEN P: Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004; 50: 953-60.
21. PINCUS T, SOKKA T: Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? J Rheumatol 2001; 28: 1723-34.
22. SOKKA T, HÄKKINEN A, KRISHNAN E, HANNONEN P: Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004; 63: 494-7.
23. KONSTAM V, SALEM D, POULEUR H et al.: Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol 1996; 78: 890-5.
24. JUSTICE AC, AIKEN LH, SMITH HL, TURNER BJ: The role of functional status in predicating inpatient mortality with AIDS: A comparison with current predictors. J Clin Epidemiol 1996; 49: 193-201.
25. CUNNINGHAM WE, CRYSTAL S, BOZZETTE S, HAYS RD: The association of health-related quality of life with survival among persons with HIV infection in the United States. J Gen Intern Med 2005; 20: 21-7.
26. KAUPPI M, SOKKA T, HANNONEN P: Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis and in a community population. J Rheumatol 2005; 32: 807-10.
27. HELIÖVAARA M, AHO K, AROMAA A, KNEKT P, REUNANEN A: Smoking and risk of rheumatoid arthritis. J Rheumatol 1993; 20: 1830-5.
28. KRISHNAN E, SOKKA T, HANNONEN P: Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther 2003; 5:R158-R162.
29. MÄKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year follow-up study. J Rheumatol 2005; 32: 796-800.
30. MÄKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005.
31. PINALS RS, MASI AT, LARSEN RA et al.: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
32. HARKNESS EF, MACFARLANE GJ, SILMAN AJ, MCBETH J: Is musculoskeletal pain more common now than 40 years ago? Two population-based cross-sectional studies. Rheumatology (Oxford) 2005; 44: 890-5.
33. KRISHNAN E, HÄKKINIEN A, SOKKA T, HANNONEN P: Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1350-2 (E-pub 2005 March 10).
34. VUORELA J, SOKKA T, PUKKALA L, HANNONEN P: Does Yttrium radiosynovectomy increase the risk of cancer in patients with rheumatoid arthritis? Ann Rheum Dis 2003; 62: 251-3.